CAR-T cell therapy for late-relapse aggressive lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a special immune cell therapy (CAR-T cells) for people with a type of aggressive lymphoma that returned more than a year after first treatment. It aims to see if this therapy can help control the cancer again.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a type of aggressive B-cell lymphoma (like DLBCL) that came back after 12 months to 5 years after finishing your first treatment
- You received only one prior line of chemotherapy that included rituximab and a CHOP-like regimen
- Your cancer shows up on a PET scan and you are healthy enough for a stem cell collection procedure
- You do not have active lymphoma in the brain, serious heart or lung problems, or other significant medical conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests CY-219, a type of cell therapy that trains your immune cells to fight B-cell lymphoma that has come back or stopped responding to standard treatments. The study evaluates whether this approach is safe and effective for patients like you.
This trial tests a CAR-T cell treatment made to target CD19 on lymphoma cells (PL001). It’s for people whose B-cell lymphoma has come back or not responded to standard treatments, aiming to shrink the cancer and help control the disease.
This trial tests a two-step treatment for patients with an aggressive type of blood cancer (large B-cell lymphoma) that has come back or didn't respond well to standard therapy. You'll receive a stem cell transplant followed by CAR-T cells—specially engineered immune cells designed to fight cancer.
This trial studies a lab-made immune cell treatment (CAR-T) for adults who have HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It aims to see if the treatment can control the lymphoma safely in this specific group.
This trial tests a type of immunotherapy called CAR-T cell therapy, which uses your own immune cells to fight lymphoma. It is for people who have already responded well to a second round of chemotherapy and are at high risk of the cancer coming back. The goal is to see if this treatment can keep the cancer away longer.
This trial tests a special cell therapy called CAR-T that targets CD19 on lymphoma cells. It is for people with aggressive large B-cell lymphoma that has not responded to standard treatments or has come back after treatment.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.